Skip to main content

Table 1 Demographic and clinical data for the Memory Malmö ‘discovery’ cohort

From: Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease

 Control Aβ-Control Aβ+MCI- Aβ-MCI- Aβ+AD (Aβ+)P-valuea (group differences)
Sample size (n)4151425075161 
Sex (F/M)256/159100/4220/3033/42104/570.000061
Mean age in years (SD)71.7 (5.21)72.99 (4.78)68.8 (5.12)72.29 (4.93)74.58 (7.37)1.676 × 10−10
MMSE mean (SD)29.11 (0.9)29.02 (0.83)27.3 (1.68)26.56 (1.79)21.47 (3.9)9.4022 × 10−213
APOE (1 or 2 ɛ4 alleles)22.89%57.75%20%74.67%66.46%7.0724 × 10−32
Anti-inflammatory drugs9.64%7.75%4.00%9.33%6.21%0.52
Platelet inhibitor drugs16.39%17.61%38.00%33.33%29.19%0.000016
Antidepressive drugs6.75%7.04%32.00%16.00%22.98%1.3371 × 10−10
Lipid-lowering drugs26.02%30.99%42.00%37.33%29.81%0.07
Antihypertensive/cardioprotective drugs41.69%49.30%54%52%54.04%0.04
Current smoker9.4%2.82%8%5.33%9.94%0.08
Mean Aβ42 in pg/ml (SD)752 (253)423 (175)628 (223)280 (90)305 (132)6.3545 × 10− 119
Mean Aβ40 in pg/ml (SD)5847 (2042)6566 (2373)4956 (2045)5057 (1612)5470 (2179)4.9837 × 10−8
Aβ42/40 ratio - log2 transformed (SD)2.05 (0.17)2.75 (0.28)2.05 (0.17)2.89 (0.28)2.9 (0.29)7.8397 × 10−253
Mean total tau (SD)292 (89)432 (163)295 (110)515 (181)649 (221) 
Mean phospho-tau (SD)37 (13)66 (35)40 (17)105 (46)123 (47) 
  1. Demographics are provided for participants who were included in the final proteomics analysis after quality assessment (see Methods)
  2. aTo assess group differences we used a test of independence (Chi-square) for categorical variables and ANOVA for continuous variables